Trial Profile
An Open Label, Phase II Study to Evaluate the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Adult Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Tenalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors Rhizen Pharmaceuticals
- 16 Oct 2020 Status changed from active, no longer recruiting to completed.
- 30 Jun 2020 Planned primary completion date changed from 1 Oct 2020 to 22 Sep 2020.
- 30 Jun 2020 Status changed from recruiting to active, no longer recruiting.